 Our hypothesis is that large-dose, extended-interval vancomycin 30 mgkg IV q24h administration provides non-inferior clinical efficacy and microbiological efficacy to standard vancomycin 15 mgkg IV q12h administration for skin and soft tissue infections in an outpatient setting. 